Activity Overview
This online, on-demand virtual symposium brings together renowned experts in HR+/HER2– metastatic breast cancer. In this educational program, these experts review recent clinical findings, discuss their potential implications for current practice, and provide actionable guidance for optimizing patient care.
This
educational activity is an archive of the live symposium held on May
27, 2026.
Target Audience
Medical
oncologists, advanced practice providers, nurses, and other health care
providers who are involved in the management of patients with advanced or
metastatic breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Identify approved and emerging oral SERDs for the management of HR+/HER2– breast cancer.
- Assess emerging clinical trial and real-world evidence to gain practical insights into the appropriate use of oral SERD-based treatment strategies for patients with HR+/HER2– MBC.
- Integrate clinical trial data, real-world evidence, and patient- and disease-specific factors to inform personalized treatment decisions for patients with HR+/HER2– MBC.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
